Summit Therapeutics Long Term Debt

Summit Therapeutics (SMMT) currently reports a long-term debt of $17M as of June 2026. That compares with $2.4M in the prior-year period — up 591.3% year over year. Use the charts on this page to explore Summit Therapeutics's long-term debt history and peer comparisons.

Summit Therapeutics's long-term debt increased from $2.4M to $17M — a 591.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Summit Therapeutics reported $17M in long-term debt as of June 2026. That compares with $2.4M in the prior-year period — up 591.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Summit Therapeutics, and consider following SMMT for alerts when major investors trade the stock.